Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer

Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer

Previously, we reported the modest but durable anticancer activity of regorafenib/nivolumab in mismatch repair-proficient (pMMR) refractory colorectal cancer in our I/Ib study. Our finding suggests the necessity of biomarkers for better selection of patients. Baseline clinical and pathological chara...

Full description

Bibliographic Details
Main Authors: Dae Won Kim, Young-Chul Kim, Bence P. Kovari, Maria Martinez, Ruoyu Miao, James Yu, Rutika Mehta, Jonathan Strosberg, Iman Imanirad, Richard D. Kim
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Cancers
Subjects:
nivolumab
regorafenib
colorectal cancer
mismatch repair-proficient
biomarker
Online Access:https://www.mdpi.com/2072-6694/16/3/556

Internet

https://www.mdpi.com/2072-6694/16/3/556

Similar Items